drugset / Trial / NCT01206101

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101

Phase 2 Terminated 3 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who required only one (single-donor) islet cell transplant.

Timeline

Start
2012-03-21
Primary completion
2013-06-03
Completion
2013-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.2 mg Subcutaneous
Subject Liraglutide Peptide 1.8 mg Subcutaneous